These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30191621)

  • 1. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.
    Kristensen G; Røder MA; Berg KD; Elversang J; Iglesias-Gato D; Moreira J; Toft BG; Brasso K
    APMIS; 2018 Oct; 126(10):804-813. PubMed ID: 30191621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.
    Kristensen G; Strand SH; Røder MA; Berg KD; Toft BG; Høyer S; Borre M; Sørensen KD; Brasso K
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
    Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
    Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis.
    Kristensen G; Berg KD; Toft BG; Stroomberg HV; Nolley R; Brooks JD; Brasso K; Roder MA
    J Clin Pathol; 2019 Oct; 72(10):696-704. PubMed ID: 31331953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Proteome of Primary Prostate Cancer.
    Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
    Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
    Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
    Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
    Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.
    Huang KC; Dolph M; Donnelly B; Bismar TA
    Clin Transl Oncol; 2014 Nov; 16(11):973-9. PubMed ID: 24796295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.
    Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G
    Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
    Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
    Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
    Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.